Efficacy, Safety and Tolerability Study of Glatiramer Acetate in Subjects With Multiple Sclerosis
Study Title
- An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Teva Identifier
- GA-MS-302 | 2011-005550-57
ClinicalTrials.gov Identifier
- NCT01578785
Study Status
- Terminated
Trial Condition(s)
- Relapsing-Remitting Multiple Sclerosis
Interventions
- Drug: Glatiramer Acetate | Drug: Placebo
Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
Gender
- Female, Male
Age Range
- 18 Years to 55 Years
Trial Duration
- 03/01/2012 - 11/01/2012
Phase
- Phase 3
Study Type
Interventional
